Viatris Inc. (VTRS) Yield on Cost (YOC): 3.12%
The yield on cost (YOC) for Viatris Inc. (VTRS) is 3.12%.
VTRS Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
3.12%
Yield on Cost for VTRS
VTRS now pays $0.48 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-20) | $45.38 | 1.06% |
| 5 years ago(2021-06-16) | $15.22 | 3.15% |
| 3 years ago(2023-06-16) | $10.29 | 4.66% |
| 1 year ago(2025-06-23) | $8.85 | 5.42% |
| Buying today(at $15.37) | $15.37 | 3.12% |
If you buy today and the dividend keeps growing
Projection: starting from today's 3.12% yield, assuming the dividend keeps compounding at its historical 8.0% rate. Boards set dividends each year, so actual figures will differ.
Today
3.12%
In 3 years
4.54%
In 5 years
5.83%
In 10 years
10.89%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Viatris Inc. (VTRS).
Starting Yield
3.12%
Ending YOC
9.92%
Year 15 Dividend
$1.52
Cum. Dividends Recd.
$14.09
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $0.48 | — | 3.12% | $0.00 |
| Year 1 | $0.52 | +8.01% | 3.37% | $0.52 |
| Year 2 | $0.56 | +8.01% | 3.64% | $1.08 |
| Year 3 | $0.60 | +8.01% | 3.94% | $1.68 |
| Year 4 | $0.65 | +8.01% | 4.25% | $2.34 |
| Year 5 | $0.71 | +8.01% | 4.59% | $3.04 |
| Year 6 | $0.76 | +8.01% | 4.96% | $3.80 |
| Year 7 | $0.82 | +8.01% | 5.36% | $4.63 |
| Year 8 | $0.89 | +8.01% | 5.78% | $5.52 |
| Year 9 | $0.96 | +8.01% | 6.25% | $6.48 |
| Year 10 | $1.04 | +8.01% | 6.75% | $7.51 |
| Year 11 | $1.12 | +8.01% | 7.29% | $8.63 |
| Year 12 | $1.21 | +8.01% | 7.87% | $9.84 |
| Year 13 | $1.31 | +8.01% | 8.50% | $11.15 |
| Year 14 | $1.41 | +8.01% | 9.18% | $12.56 |
| Year 15 | $1.52 | +8.01% | 9.92% | $14.09 |
Viatris Inc. Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Viatris Inc. (VTRS)?
- The yield on cost (YOC) for VTRS stock is 3.12%.
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith